Home Biosciences provides financial support and operational guidance to create the groundbreaking therapies of the future.
The company, Europe’s first venture builder fully dedicated to biotech, works with leading scientific teams to build and grow sustainable businesses by assembling the right expertise and structure. Each project is housed in a dedicated subsidiary, fully financed by Home Biosciences and led by teams entirely focused on the day-to-day execution of its projects.
Home Biosciences is the partner of choice for academics and scientists who seek to transform their innovations into life-changing therapies for patients.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.